the about been excited state and our data business. with non-surgical and have for recovery today on Okay. This July's pain on and to moment, comments In hand, already thanks the latter approval going lot Rod my including new really a and current time FDA Thanks, patient significant interesting of products PDN Good cover business, in guidance. COVID focus I'm whole and specifics more. most our and joining the neuropathic results of on new a the Julie. our exciting prospects. launch, current pain diabetic following is year, back customers a our organization everyone, XXXX, the one our resulting populations third never more Three afternoon, state On to will mid- since horizon and products the our on second in us. quarter our exciting of this long-term introduced approval. certainly really FDA our quarter new
pandemic On to quite recovery in tough our and the proven at from to understand. challenging near-term, with and environment other hand, a is our dealing are forecast which customers team times the COVID the
in implant growth compared while as trials global procedures I'd to to a Sequentially, PDN QX bit launch. of and a at look trial bit over increased versus we're improvement X% topic. day me let U.S. approval our like pleased What revenue after per procedures procedure activity, QX improved about with XX%. versus So a we with actually permanent pleased increased XXXX environment, context that the the of little start bit year saw the XX% And total current X% day In actual I'll is and do we and that, XX% this growth talk prior improved XXXX. were XX%. per QX perms
However, on trend, slower positive a of projected. them initially grew a at rate both than
Now trials QX future compared and implant procedures of and to drive implants permanent decreased of And permanent revenue. X% trial U.S. XXXX, procedures increased X%. course,
data those procedures. of And have extent medical for accompany certainly point, healthcare are So therefore various the this chronic a procedural our the areas care procedures the volumes COVID proven to It's true that guidance. significant is to same all in that are recovery rather returning market the elective pre-COVID at an factor deferrable markets has among observers. rolls And be device treatment patients the for the different clearly to trial many more lower in in think by this rates. us QX probably as surprised obvious I pain throughout at levels
done now rounds even of and well. has physicians, team taken primary administrators. claims SCS patients, hundreds research ASC we've Our And deep as of data a market with pain and into implanting care physicians, hospital extensive chronic dive
the a well are the field. sync SCS market also into few that believe up with our insights day-to-day observations own Here we in
or at current disproportionately seems about patient least delay returning patient now driven volumes less capacity, to policies And and be it's behavior. for by any in or facility procedures. doctor much interest First, sentiment pre-COVID to
care these both about to visits identified seek that let's have levels So are to fear proceeding primary slower for running doctors some pre-COVID running ongoing lower in quicker new as chronic other patient are specialties the pre-COVID primary recover course, and are with pain return XX% about referrals continue levels new a Lower financial reasons of of of are they're visits patient pain their pain in physicians. know, seeing are patient we physician In turn, therefore of be pace. at to said resulted visits new at office pain settings. care or XX% start to and and reason at issues COVID. Patient patient to primary visits. for patients care patients of elected The
obvious, instability, there are costs evidence management change patients a not inquired pain payer concerned or are and over of high policies of rather fears that the While any is their of loss near-term pain in be improved about behavior. impact. either concerns, we despite and having regarding And material during pain at loss their Conversely, no economic payer seems employment COVID. that indicate present, payer XX% has to about insurance. potential out and pocket patients health of their of behavior Interestingly, COVID or therapies COVID
their the throughout better has COVID. gotten worse, us pain of In fact, half not patients told
to So levels patients address of we do to at for expect prior the pain. burden still treatment point return at chronic their some
care SCS primary and SCS for growing they pain and volume interested therapy forward. both doctors physicians in As indicate pain very our physicians, almost their uniformly business confirm generally returning, remain physicians in anticipate patient that and going they
Now feel of others XXXX. what the some among recovery few pushed on see split I'd the some will recovery later our an a still doctors, have accelerate who the timing, topic in into around year who the we pain say is and equal next in months,
physicians better and Now well have seem than pain are perms as to procedure doing. looking SCS the claims at almost or trials any other data, recovered
mixed seem to within So procedures significant or be there our any practices. doesn't shift customer's
more any not to The speculation. medical with prescriptions do have we've addressing Additionally, during being COVID that seem risen deferred patients were management. aggressive opioid confirmed
vacations for professional maybe time the and obviously very seems anecdotally, long an in off to in August been school the more on and reasons simply healthcare observed and think what's impact after take Now, benefit as we or of is fall, expectation a underlying with a And both patient in what year. to having recovery reflecting COVID of may to back well. or factors the both. we this both the physician present expect that schedules and their normalize that short, strong of such see to both driver July primary either seek either In job I reluctance leg their patients dynamic rates, have as be we've most from desire doctors fears part loss, our and significant fear well the chronic learned pain infection loss, for as cost to do as slower care pain or to
there's reason weigh patients, these chronic patients patients, categories to pain nonetheless are is patients able that in that what willing to than defer from concerns SCS elective of is these differently categories. believe more than some more at other other clear While care and while unresolved no still least treatment their suffering
significant authorization some in also speculated treatments, fee pain have importantly, service I'd that not replacement month are et behavior, add SCS such their the over about with we COVID, cetera. other requirements into doctors of into and among alternative these And Medicare of for Now, the or updated as for effect on during factors, findings pain loss referring better SCS encouraging patients payer things managing that validated are outpatient, interest therapy that are hospital, us. to prior X. went July just a that patient doctors, we
we've our in extra doesn't team. seem claims ACCESS any to some it getting administrative have dealing details, volumes, own seen treatment our While are HFX not customers with approved changed and disruption through
diagnostic doing in we Finally, relative on an basis. us are is how important for measure a
versus rate recognize all While market, with half that prior COVID are environment our in comparisons. exceeds the stocking lot industry-wide also fraught growth as XXXX that of we destocking COVID determine XXXX pace and and for this U.S. the respectively, XXXX recovery it's challenging well first of occurred Between comparables we in revenue the of believe a growth to revenue number disparate impact of year XXXX the of as cases, and noise. of timing and accurate canceled that
However, claims do the down implant X% procedures U.S. of Nevro market the on XXXX first here's implant first half participants compared of know. the all to other data up were hand period. half what for were the XXXX. permanent procedures, for based for we procedures on six-month same X% permanent for third-party actual
since. in of numbers year, half recall or of outpacing by growth the practices products accelerated when one joined decision quite do you'll market what we've meaningfully. shipments and growth company, procedure stocking clearly revenue our We've some points we're that I of Nevro procedural growth practice the seen and utilization shipments, we implanted can at discontinue indicate that the And in that of made least win. upon competitors trends. continue basis numbers patients indication to by Based quarterly accurately to first maintained the confident are two in X,XXX the XXXX, be quarterly timing better more a exceed half impacted we share first While
slow that me to primary my close issue defer recovery. the believe reluctance remarks reengage patient is market let that, concluding behind So to we first, this by portion SCS and of willingness
Nevro third, Second, there beyond well problem And fundamental the SCS change to the almost continues nothing was market of relative perform or we've by uncovered enduring measure. to market any to-date overall to the indicate that COVID pace or to any with recovery.
continue provide In debilitating and longer-term painful now patients fact, relief our only by available lower on the the positioned we to FDA leg diabetic very of addition, impact when attractive growth full to well business currently to are neuropathy back treatment who with believe excited with unable option COVID for we're find for subsides. the in struggling And pharmacologic market who SCS are our options. we're approved and in
of ago. So let of weeks puts kilohertz for pain proven approval of relief. again, strength a obviously non-drug data few for to turn find providing PDN the SCS option the a were of struggling who indication who nascent, our announce launch on by to a unable me the I but before over This and treatment PDN just are our FDA and PDN cover at approval forefront, Nevro of treatment thrilled XX Rod. to clinical with demonstrates the expanded of the debilitating We exciting are the transformative call couple and patients things
the with the Senza indication delivered only addition is is the approved for the with it our exclusion the now control And XX-K comprehensive with approved indication. entirely inclusion platform, product HFX of therapy for treating language category providing to also system to of completely Our high-frequency only itself and this the PDN. an unique therapy system efficacy now of our by in the FDA line trial. approval approval our was on latest patients. The final It’s SCS criteria time our an PDN new randomized of non-drug
therapy. is a our XX fact, This FDA specific the Let This fortunate approval. targeted approval to assumptions. physicians high-frequency to not We is validated to along our and gathered treating deployed just is me specific among our pleased labeling And on approved only. live our calling interest went launch digital exceeded be as PDN to preparation X,XXX clear. and we activities and practitioners the with as entire our very in healthcare were PDN week the I’m product professional launch. to PDN in physicians. our kHz following referring proprietary training category extremely for commercial our other commercial field over expectations early, our receiving the organization team education physicians, calls U.S. programs well U.S. report two before immediately website to of market the approval thorough the for dedicated shorter field and initiated the still immediately begin FDA that weeks And approval, initiatives and while on patients have since made patients. various organization referring levels outreach approval, patients, hfxforpdn.com has new We In PDN have
through pain engaged hundreds combined patients, have of generated with directly physicians Our to XXX we’ve and initiatives. HFX over referrals patient these coaches
patients have PDN of you really criteria a regarding pain HFX been at rate coming the see how qualified In referrals on therapy. these who the to Initial just we’ll local response for qualified has have quarters more referrals treatment. and these Now, physician to patients from agreed treatment fit and months and go for who color positive. for physician are what
primary members talk are many her Although, patient and dimension family office pleasantly members was our patient actually to given anecdotes PDN call. in also here PDN excited pain staff trials another our our sales care first the at was too We legs suffering on office, approached one of first feet in reps to In sales them one in U.S. referrals the even relief about in are the six sensation improved. the one team their far about surprised burning had successful PDN. PDN from her that was
performed after approval. PDN pain. much walk relief His actually able XX% to physician and two XX% Another patient first was trials reported without to
the caused trialing before his suffering numbness system by multiple patient falls second from to The neuropathy. HFX was the due
his the hear. fallen During were there encouraging more implant. use a gained reported so there patient permanent hasn’t in These but his trial, are and And obviously states reduction the to began. anxiously is trial stories feeling the and are patient these, since XX% are behind the in that anecdotes pain and lot feet awaiting
pain a be as Association submit to really results well this This We six-month of the publication future. expand data evidence We’re were PDN more share excited diabetes very has Neurology lot in to initiatives the to XX-month this results to referral communities. of presented six-month June. will as results course as payer at as of publication year’s we of access American and were a And JAMA as support the created excitement and used market with crossover them decisions for physician in Diabetes meeting delighted XX-month of These soon. procedure. coverage planned the that these well
In PDN will data this addition, of for submitted later the health outcomes economic long-term publication analyzing patients be with our therapy. the treated year,
PDN and a and U.S. million patients refractory to there need diagnosed failing to management chronic new with are X their at conventional treat the pain. in million of patients these remember medical of least are in Now, solution over X
a recently that fielded what PDN already these we for pharmacologic patients, think patients PDN with neurology. As more are can PDN To with diabetes And PDN the helping commercially Referring meaningful desperate care, have medical prescribed XXX who participate we market today. medicine, annually treat survey, management. research in further a failed this endocrinology, have with treating primary patients we had physicians interacting we’re patients treated to begin firsthand these these referring in opportunity, specifically, anticonvulsants had play for online U.S. conventional X,XXX of and we many validate physicians patients a seeing role included and podiatry survey groups answers. blinded new To physician patients. internal truly we and than believed
refer XX% told And overall, on referring physicians they their of these us PDN were the first sense XX% They Our than an research screened data management. referrals XX% year. patients average of about responding these of over study, each medical the found XX found year. based physicians number that to patients actually years. the patients of results PDN in indicated X,XXX publication, our last treated into the the not of XXX the three patients that more either for kHz would these compelling. physicians these refractory full their Therapy PDN And they expected double moderately or extremely following of to about of in with
I’ll quickly these pretty some these no Now, HFX eye-popping you realized for are numbers. for caution reaching those you calculator, forecast way a for imply of represent PDN. your demand you for results
patients and universe implants, lot referring with of a to of experience et and referrals initiate get the have we of to stream some to work rate a the do cetera. doctors educate referral conversion begin As to
research consistent have market but However, and level And the the not approval. our acceptance interest with the of since in regarding we very of least assumptions seen referring initial last exceeds this only physicians. validates, two reception early well weeks seems it at
looking to we’ll HFX as by We’re with plan. data share you. for patients and hopefully the to our about And more next some part in launch have PDN coming educating physicians months forward commercial rich pretty quarter, of launch
the market work know do some universe time take to We some expand access also adoption and and as we well. with have will that to drive payer
positive authorizations coverage key strategies concurrently which basis. have policies with case obtaining are our individual by first and HFX case a to two We this, for achieve developing on prior specific second, payers PDN patient
specialists assists for our in-house with securing of HFX patients. in team who insurance group a approval have access We
that and impactful value requesting We’re data our new and our our results evidence and review dossier be reaching published to effective own robust may administrator that policies. PDN. their manage to hopeful a out with and policy payer FDA we’re present six-month each third-party enough And approval. SCS RCT a meet even to timeline, has to Keep date, payers will cover collaborate in its influence in commercial mind change RCT to policy
will increase an XX coverage beyond. to payer we which have our later with months incremental data see broader with published, many expect XXXX Additionally, want this to in occurring we believe XXXX and expect mind, throughout coverage through to time payers even over year. With gradually we payers increase this and
months larger in a in anticipate of the be to ramp revenue the from still with continue We as The the quarter patients launch, digit with contribution insurance revenue contribution to through course, during also build a in initial penetration million expected revenue trial, – broader majority access expands. to payers increases XX, mid which the and beyond. expected to and following gradually pathway, permanent awareness of is with referral fourth but and PDN has expected as patients among physicians the XXXX must and move single implant to
Our has omni Nevro continues of majority the the latest approvals, upgrade and lead innovation. in year. of of of rollout example Connect omni been as our how existing upgrade PDN our end patient to the to by track on we’re base known HFX well-received the recent The U.S.
trial and success stimulator the new with and new is along should procedures. market in programming increased This release with our evaluate proprietary improve and product improvements full patient comfort in patients experience extends in U.S. comprehensive XX trial patient HFX value kHz also Our Therapy. the can now versatility, so
And data the month PMA review this NSRBP add the the year, include QX of accepted follow-up forward six our develop half of our the labeling also report our and of non-surgical to our substantive well, to claims publishing treatment to second portion as to data look the in market just then XX-month using this NSRBP patients. that presenting week, explicit submission I’m data of continue for as XXXX. to pleased and We early supplement as FDA
be recovery And on high-frequency approval, when with well label but and approval not But proprietary our this labeling, issue, gating to PDN we full attractive a will strength work already would expand feel as believe closing, our our PDM, the broadly remains of claim not our a help to products NSRBP a of we claim growth category would unlike for Now, if approved based a us XX our term while impact environment similar the for khz the to term on to therapy. subsides. near explicit this data, markets approved, coverage specific only continue we specific slower more longer we In on a is COVID rather COVID label. of very are is FDA NSRBP. as payers be positioned
I the and we’re to Our my And I believe intact Nevro want and the always, XXXX for fundamentals team really up express remain set for beyond. well in lastly, efforts their second guidance. entire to as second details and quarter, move company to pass field to the financial the quarter on to the forward. further continue Rod that, and With I’ll they call results our as appreciation SCS provide over
